Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
Authors
Falchi, L.Leppa, S.
Wahlin, B. E.
Nijland, M.
Christensen, J. H.
De Vos, S.
Holte, H.
Linton, Kim M
Abbas, A.
Wang, L. W.
Dinh, M.
Elliott, B.
Belada, D.
Affiliation
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY;Issue Date
2022
Metadata
Show full item recordCitation
Falchi L, Leppa S, Wahlin BE, Nijland M, Christensen JH, De Vos S, et al. Subcutaneous epcoritamab with rituximab plus lenalidomide (R-2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301985.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.7524Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7524Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.7524